MedPath

CORNEAL CONSULTANTS OF INDIANA, P.C.

CORNEAL CONSULTANTS OF INDIANA, P.C. logo
🇺🇸United States
Ownership
Private
Established
1983-01-01
Employees
11
Market Cap
-
Website
https://pricevisiongroup.com

Clinical Trials

10

Active:0
Completed:5

Trial Phases

3 Phases

Phase 2:6
Phase 4:1
Not Applicable:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials

Phase 2
6 (66.7%)
Not Applicable
2 (22.2%)
Phase 4
1 (11.1%)

Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection

Phase 4
Completed
Conditions
Corneal Endothelial Dystrophy
Corneal Edema
Interventions
First Posted Date
2021-11-29
Last Posted Date
2024-08-14
Lead Sponsor
Price Vision Group
Target Recruit Count
70
Registration Number
NCT05136443
Locations
🇺🇸

Price Vision Group, Indianapolis, Indiana, United States

Corneal Crosslinking for Treatment of Corneal Neovascularization

Phase 2
Recruiting
Conditions
Corneal Neovascularization
First Posted Date
2021-03-08
Last Posted Date
2025-07-31
Lead Sponsor
Price Vision Group
Target Recruit Count
62
Registration Number
NCT04787471
Locations
🇺🇸

Price Vision Group, Indianapolis, Indiana, United States

Effect of Xen Implantation on the Aqueous Humor Proteome

Terminated
Conditions
Primary Open Angle Glaucoma
First Posted Date
2019-10-28
Last Posted Date
2022-03-03
Lead Sponsor
Price Vision Group
Target Recruit Count
3
Registration Number
NCT04141865
Locations
🇺🇸

Price Vision Group, Indianapolis, Indiana, United States

Rhopressa for Corneal Edema Associated With Fuchs Dystrophy

Phase 2
Completed
Conditions
Fuchs Endothelial Dystrophy
Interventions
First Posted Date
2019-08-09
Last Posted Date
2021-10-19
Lead Sponsor
Price Vision Group
Target Recruit Count
29
Registration Number
NCT04051463
Locations
🇺🇸

Price Vision Group, Indianapolis, Indiana, United States

Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration

Phase 2
Terminated
Conditions
Fuchs' Endothelial Dystrophy
Interventions
Drug: Placebo
First Posted Date
2019-06-03
Last Posted Date
2023-02-06
Lead Sponsor
Price Vision Group
Target Recruit Count
19
Registration Number
NCT03971357
Locations
🇺🇸

Price Vision Group, Indianapolis, Indiana, United States

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.